Response to Comments: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis

This document (A59483) records responses to public comments on the MolDX LCD L39424 (DL39424) concerning molecular biomarker testing to guide targeted therapy in rheumatoid arthritis. It notes the comment period (09/01/2022–10/15/2022), the notice period beginning 08/31/2023, and an LCD effective date of 10/15/2023. The document itself does not state coverage indications or limitations; consult LCD L39424 for the actual coverage criteria.

"This document contains responses to public comments only and does not define coverage criteria; refer to MolDX Local Coverage Determination L39424 (DL39424) for the coverage policy on molecular bio..."

Sign up to see full coverage criteria, indications, and limitations.